Therapy News and Research

RSS

ICGC: New era of personalised medicine for cancer patients

Published online today in Nature, a paper authored by over 200 members of the International Cancer Genome Consortium describes the beginnings of a Brave New World, a new era of personalised medicine for cancer patients.

15 Apr 2010

ProCure Proton Therapy Center treats cancer patients with proton therapy technology

The world's first inclined beam treatment room is open and treating patients at the ProCure Proton Therapy Center in Oklahoma City. The third of four treatment rooms at the Oklahoma Center is treating a wide range of tumors with proton therapy, an important alternative to X-ray radiation in treating cancer.

15 Apr 2010

New findings may aid in developing medications for atherosclerosis and insulin resistance

Scientists from Eastern Virginia Medical School (EVMS) recently presented preliminary research findings that identify a specific gene as a potential new target for treating obesity-related diseases.

15 Apr 2010

Phase II clinical study examining CTT's Calmare pain therapy medical device completed

Competitive Technologies, Inc. announced today that Thomas J. Smith, MD FACP, and co-investigator Patrick J. Coyne, MSN, APRN, FAAN, of Virginia Commonwealth University's Massey Cancer Center have completed their open Phase II clinical study examining CTT's Calmare pain therapy medical device's efficacy treating patients suffering with severe pain from chemotherapy induced peripheral neuropathy.

15 Apr 2010

BIOTRONIK launches new Reocor external pacemakers following European CE Mark approval

BIOTRONIK SE & Co. KG today announced the European launch after receiving CE Mark approval for its new Reocor external pacemakers, available in two models for dual and single chamber pacing therapy.

15 Apr 2010

Study suggests patients with low-back pain may benefit from chiropractic treatment

Low-back pain sufferers can seek relief from any number of health professionals, orthopedists, physical therapists and osteopaths among them.

15 Apr 2010

Enrollment complete in Jennerex' Phase 1 trial of JX-594 IV administration for solid tumors

Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today announced that it has completed patient enrollment in a Phase 1 clinical trial evaluating the intravenous (IV) administration of JX-594, the company's lead product for the treatment of solid tumors. Jennerex expects to report the results from this trial at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in May 2010.

15 Apr 2010

Hybridyne Imaging Technologies' ProxiScan gamma camera receives FDA clearance for endocavity imaging

Hybridyne Imaging Technologies, Inc., a developer of compact, high-resolution gamma cameras for the detection of cancer and other abnormalities in the body, announces FDA clearance of ProxiScan. The system can be used in imaging the distribution of radionuclides in the human body using planar imaging techniques. ProxiScan may also be used intra-operatively, on pathological specimens and for endocavity applications if a protective sheath is used.

15 Apr 2010

Florida to enact health care legislation to improve access to ARV therapy

Florida is poised to enact health care legislation that would add clarity to existing state statutes by requiring that all state-regulated health plans include lifesaving antiretroviral (ARV) HIV/AIDS drugs on their drug formularies or preferred drug lists.

15 Apr 2010

Trevena commences Phase I trial of TRV120027 biased ligand for acute decompensated heart failure

Trevena Inc., a leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, today announced the initiation of a Phase I clinical trial of TRV120027, a titratable i.v. agent designed for the treatment of acute decompensated heart failure. TRV120027 is a biased ligand that targets the angiotensin II type 1 receptor (AT1R) and induces a unique mode of signaling.

15 Apr 2010

Aspirin can reduce acute migraine attacks

A single dose of 900-1000 mg aspirin can substantially reduce migraine headache pain within two hours, for more than half of people who take it. It also reduces any associated nausea, vomiting, and sensitivity to light or sound (photophobia or phonophobia).

15 Apr 2010

AACR Annual Meeting 2010: Æterna Zentaris to present data on Erk/PI3K inhibitor compounds

Æterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it will make an oral presentation, as well as a poster presentation on Erk/PI3K inhibitor compounds, Tuesday, April 20, at the American Association for Cancer Research (AACR) Annual Meeting, to be held April 17-21, 2010 at the Walter E. Washington Convention Center in Washington, D.C.

13 Apr 2010

EntreMed commences Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

EntreMed, Inc. today announced the initiation of a multi-center Phase 2 study with its lead oncology product candidate, ENMD-2076, in patients with platinum resistant ovarian cancer. The study will be conducted at up to six sites in the United States and Canada. In addition, EntreMed received a No Objection Letter (NOL) from the Therapeutic Products Directorate of Health Canada on its Clinical Trial Application to conduct the Phase 2 clinical trial in ovarian cancer patients.

13 Apr 2010

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.

13 Apr 2010

Common sense gun laws needed to stem crippling costs of gun violence

After a spate of random shootings and gun homicides, Illinois Campaign to Prevent Gun Violence, along with doctors and medical professionals, convened at Children's Memorial Hospital to send an urgent plea to state lawmakers to require background checks on all handgun sales in order save lives and reduce escalating health care costs related to gun violence.

13 Apr 2010

Immunomedics' progress in cancer therapy product candidates to be presented at AACR 2010

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that eight presentations reporting on the Company's progress in diverse cancer therapy product candidates will be given at the 101st Annual Meeting of the American Association for Cancer Research, April 17 – 21, 2010, in Washington, DC.

13 Apr 2010

Over 17,000 scientists convene at AACR 101st Annual Meeting 2010

Scientific breakthroughs in molecular targeting, translational cancer research and cancer prevention will take center stage when more than 17,000 scientists from around the world gather at the Walter E. Washington Convention Center, April 17-21, for the AACR 101st Annual Meeting 2010.

13 Apr 2010

High level of microRNAs found in patients with high-risk multiple myeloma

Multiple myeloma researchers at the University of Arkansas for Medical Sciences (UAMS) recently discovered that widespread activity of a specific class of genes can identify aggressive, or high-risk, cases of the disease.

13 Apr 2010

'Forgotten' cells in brain cancer

Glioblastoma is a guileful enemy. While most of the brain tumor can often be removed surgically, in virtually every case the tumor reappears. One reason for this is that sporadic, infiltrative tumor cells will remain in the brain even after most careful surgery. Researchers at the University of Bonn have now subjected these 'forgotten' cells to closer scrutiny for the first time.

13 Apr 2010

Study identifies pathway linked to rheumatoid arthritis

Investigators from Hospital for Special Surgery have identified a pathway involved in turning off inflammation that does not work properly in people with inflammatory arthritis. The finding, reported in the April 23 issue of the journal Immunity, could lead to the development of new therapeutic approaches to treating arthritis in the future.

13 Apr 2010

Therapy News and Research

ICGC: New era of personalised medicine for cancer patients

ProCure Proton Therapy Center treats cancer patients with proton therapy technology

New findings may aid in developing medications for atherosclerosis and insulin resistance

Phase II clinical study examining CTT's Calmare pain therapy medical device completed

BIOTRONIK launches new Reocor external pacemakers following European CE Mark approval

Study suggests patients with low-back pain may benefit from chiropractic treatment

Enrollment complete in Jennerex' Phase 1 trial of JX-594 IV administration for solid tumors

Hybridyne Imaging Technologies' ProxiScan gamma camera receives FDA clearance for endocavity imaging

Florida to enact health care legislation to improve access to ARV therapy

Trevena commences Phase I trial of TRV120027 biased ligand for acute decompensated heart failure

Aspirin can reduce acute migraine attacks

AACR Annual Meeting 2010: Æterna Zentaris to present data on Erk/PI3K inhibitor compounds

EntreMed commences Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

Common sense gun laws needed to stem crippling costs of gun violence

Immunomedics' progress in cancer therapy product candidates to be presented at AACR 2010

Over 17,000 scientists convene at AACR 101st Annual Meeting 2010

High level of microRNAs found in patients with high-risk multiple myeloma

'Forgotten' cells in brain cancer

Study identifies pathway linked to rheumatoid arthritis

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News